Hyderabad based Aurobindo Pharma Limited has received tentative US FDA approval to manufacture and market fixed dosed combination Abacavir Sulfate/Lamivudine tablets 60/30mg for the treatment of HIV infections.
The company had earlier received tentative approvals to co-packaged Lamivudine/Zidovudine tablets + Abacavir Sulfate tables 150/300mg + 300mg and Abacavir Sulfate/Lamivudine tablets 600/300 mg. This is Aurobindo 87th ANDA approval from US FDA, a company release said.
The company had earlier received tentative approvals to co-packaged Lamivudine/Zidovudine tablets + Abacavir Sulfate tables 150/300mg + 300mg and Abacavir Sulfate/Lamivudine tablets 600/300 mg. This is Aurobindo 87th ANDA approval from US FDA, a company release said.
No comments:
Post a Comment